192 related articles for article (PubMed ID: 37237267)
1. Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy.
Klehmet J; Tackenberg B; Haas J; Kieseier BC
BMC Neurol; 2023 May; 23(1):207. PubMed ID: 37237267
[TBL] [Abstract][Full Text] [Related]
2. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Serbian version of inflammatory Rasch-built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Peric S; Bozovic I; Pruppers MHJ; Bjelica B; Stevic Z; Faber CG; Merkies ISJ; Basta I
J Peripher Nerv Syst; 2019 Sep; 24(3):260-267. PubMed ID: 31397933
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
6. Chronic Acquired Polyneuropathy Patient Reported Index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy.
Bjelica B; Peric S; Gwathmey K; Sadjadi R; Bozovic I; Burns TM; Basta I
J Peripher Nerv Syst; 2019 Sep; 24(3):247-252. PubMed ID: 31209940
[TBL] [Abstract][Full Text] [Related]
7. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Brusse E; Jacobs BC; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Fokkink WR; Nieboer D; Lingsma HF; Merkies ISJ; van Doorn PA
Eur J Neurol; 2021 Jan; 28(1):286-296. PubMed ID: 32876962
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
Hartung HP; Mallick R; Bril V; Lewis RA; Sobue G; Lawo JP; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; van Schaik IN;
Eur J Neurol; 2020 Jan; 27(1):196-203. PubMed ID: 31400231
[TBL] [Abstract][Full Text] [Related]
10. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
[TBL] [Abstract][Full Text] [Related]
11. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
[TBL] [Abstract][Full Text] [Related]
12. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA
Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
[TBL] [Abstract][Full Text] [Related]
15. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
Cirillo G; Todisco V; Tedeschi G
Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
[TBL] [Abstract][Full Text] [Related]
16. Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Bozovic I; Kacar A; Peric S; Nikolic A; Bjelica B; Cobeljic M; Petrovic M; Stojanov A; Djuric V; Stojanovic M; Djordjevic G; Martic V; Dominovic A; Vukojevic Z; Basta I
J Neurol; 2017 Dec; 264(12):2481-2486. PubMed ID: 29086018
[TBL] [Abstract][Full Text] [Related]
17. Home IVIG for CIDP: a focus on patient centred care.
Katzberg HD; Rasutis V; Bril V
Can J Neurol Sci; 2013 May; 40(3):384-8. PubMed ID: 23603176
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
[TBL] [Abstract][Full Text] [Related]
19. Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis.
Anderson-Smits C; Ritchey ME; Huang Z; Chavan S; Souayah N; Ay H; Layton JB
Neurol Ther; 2023 Aug; 12(4):1119-1132. PubMed ID: 37171778
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and determinants of pain in chronic inflammatory demyelinating polyneuropathy: Results from the German INHIBIT registry.
Mork H; Motte J; Fisse AL; Grüter T; Brünger J; Stoykova Z; Bulut Y; Athanasopoulos D; Sturm D; Tegenthoff M; Gold R; Enax-Krumova E; Pitarokoili K
Eur J Neurol; 2022 Jul; 29(7):2109-2120. PubMed ID: 35357725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
